Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500821 · ClinicalTrials.gov registry record · NA
Evaluation of the LipiFlow System With a New Activator
A NA study, sponsored by Johnson & Johnson Surgical Vision.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT04500821 is a NA study that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 44 participants.
The verdict
NCT04500821, a NA study, has completed, sponsored by Johnson & Johnson Surgical Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the questionnaire will be used to assess the clinical utilization of the Activator LFD-2100. This study will be conducted in up to four sites in the USA.
Interventions
- DEVICE Activator LFD-2100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04500821
The ClinicalTrials.gov registry entry for NCT04500821 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Surgical Vision, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Activator LFD-2100 is the first listed.
NCT04500821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04500821 about?
NCT04500821 is a clinical study titled "Evaluation of the LipiFlow System With a New Activator". Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the q...
What is the current status of trial NCT04500821?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2020-10-02. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04500821?
The interventions under investigation include: Activator LFD-2100 (DEVICE).
Who is sponsoring clinical trial NCT04500821?
This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.